Please ensure Javascript is enabled for purposes of website accessibility Global Life Sciences Fund - Janus Henderson Investors
For Approved Qualified Domestic Institutional Investors in China

Global Life Sciences Fund

By understanding the science and business of health care, our experienced team invests in companies addressing unmet medical needs or those that seek to make the health care system more efficient.

ISIN
IE0009355771

NAV
USD 54.20
As of 2024/05/16

1-Day Change
USD -0.08 (-0.15%)
As of 2024/05/16

Morningstar Rating

As of 2024/04/30

Overview

INVESTMENT OBJECTIVE

The Fund aims to provide capital growth over the long term.

More

The Fund invests at least 80% of its assets in shares (also known as equities) selected for their growth potential and with a life sciences orientation. The Fund may invest in companies of any size, in any country.

Less

ABOUT THIS FUND

  • Looks to invest in companies addressing unmet medical needs or those that seek to make the health care system more efficient
  • Aims to maintain a balanced portfolio across subsectors (biotechnology, health care services, medical devices and pharmaceuticals)
  • An experienced team of specialists that seeks to understand the science and the business of health care

PORTFOLIO MANAGEMENT

Andy Acker, CFA

Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Daniel Lyons, Ph.D., CFA

Portfolio Manager | Research Analyst

Industry since 2000. Joined Firm in 2000.

Performance

Cumulative Performance (%)
As of 2024/04/30
A2 USD
 
  Cumulative
  1MO 3MO 6MO YTD 1YR 3YR 5YR Since Inception
2000/03/31
A2 USD -4.80 0.25 18.50 2.89 6.27 8.97 55.49 420.10
Calendar Year Returns (%)
As of 2024/03/31
A2 USD
2023 2022 2021 2020 2019
A2 USD 5.44 -4.35 4.72 23.41 27.06
Calendar Year Returns (%)
Year A2 USD Index
2023 5.44 3.76
2022 -4.35 -5.41
2021 4.72 19.80
2020 23.41 13.52
2019 27.06 23.24
2018 2.01 2.51
2017 20.55 19.80
2016 -13.79 -6.81
2015 5.69 6.60
2014 32.75 18.10
2013 52.45 36.27
2012 22.47 17.54
2011 6.08 9.46
2010 6.04 2.41
2009 24.46 18.89
2008 -31.08 -21.50
2007 19.64 3.94
2006 -3.74 10.47
2005 9.89 9.00
2004 12.36 6.00
2003 25.55 19.50
2002 -31.32 -17.98
2001 -20.46 -13.24
2000 from 31/03/2000 16.80 25.65
FEE INFORMATION
Initial Charge 5.00%
Annual Charge 1.50%
Ongoing Charge
(As of 2022/12/31)
2.40%

Portfolio

Top Holdings (As of 2024/04/30)
% of Fund
Eli Lilly & Co 8.24
UnitedHealth Group Inc 6.03
Novo Nordisk A/S 5.67
AstraZeneca PLC 3.95
Merck & Co Inc 3.71
AbbVie Inc 3.48
Sanofi SA 2.61
Boston Scientific Corp 2.43
Abbott Laboratories 2.39
Amgen Inc 2.27
TOTAL 40.78
Sector Allocation % of Fund % of Fund As of 2024/04/30
Regional Allocation % of Fund % of Fund As of April 30, 2024

Documents